Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-04-01

Study Completion Date

2020-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the clinical features and long-term outcome of anti-neutrophil cytoplasmic antibody (ANCA)-positive interstitial lung disease (ILD) and assess the difference between microscopic polyangiitis (MPA) associated ILD and isolated ANCA-positive idiopathic interstitial pneumonia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Study of Differences in Eosinophil Function and Subsets in Patients With Eosinophilic Pulmonary Diseases

NCT06944418

Eosinophil Subtype Eosinophilic Pulmonary Diseases

RECRUITING

The Role of Standardized Training in the Diagnosis of Interstitial Lung Disease by Transbronchial Lung Cryobiopsy

NCT06245954

Transbronchial Lung Cryobiopsy

RECRUITING NA

Open Label Trial of Utility of Cryobiopsy in the Multidisciplinary Diagnosis of Idiopathic Interstitial Lung Disease

NCT02563730

Interstitial Lung Disease

UNKNOWN NA

Detection and Prediction of Clinically Significant Pneumothorax After Image-guided Transthoracic Lung Biopsy

NCT06563167

Lung Biopsy

RECRUITING

The Diagnostic Yield and Safety of Transbronchial Cryobiopsy in Diffuse Parenchymal Lung Diseases

NCT03704233

Diffuse Parenchymal Lung Diseases

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ILD patients with serum ANCA-positivity were enrolled in this study.

1. Baseline data collection:

1. Demographics information (age, gender)
2. Clinical course
3. Clinical symptoms and signs (cough, dyspnea, fever, fatigue, crackling, clubbing fingers, mechanics hand)
4. Laboratory findings (blood and urine routine, liver and renal function tests, erythrocyte sedimentation rate, C reactive protein)
5. Serologic tests (ANA , Rheumatoid factor , Anti-cyclic citrullinated peptide (CCP), Anti-dsDNA, Anti-Ro (SS-A), Anti-La (SS-B), Anti-Smith, Anti-Scl-70, Anti-Jo-1)
6. Systemic manifestation if diagnosed as systemic vasculitis
7. Pulmonary function tests (ventilation and diffusion capacity test)
8. Chest high-resolution computed tomography (HRCT)
2. Treatment: treatment will be given according to the experience of each pulmonologist.
3. Follow-up:

1. Patients were followed up at least once a year and basic laboratory tests, serologic autoantibodies, pulmonary function test and chest HRCT were evaluated routinely
2. Follow-up end point was April 2019.
4. Outcome

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interstitial Lung Disease Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females
* Aged from 18 to 85 years with informed consent
* Have a diagnosis of ILD based on clinical symptoms and radiologic features, with or without histopathologic results
* Have available ANCA testing results during the first visit and follow-up period

Exclusion Criteria

* Connective tissue disease associated ILD
* ILD induced by drug, environment, or occupational exposure
* Hypersensitivity pneumonitis and sarcoidosis

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No